Is Cytokinetics, Incorporated overvalued?

Cytokinetics, Incorporated (CYTK) — key valuation metrics and fundamentals.

No verdict

Price

$56.13

Fair value

—

Current P/E

—

Normal P/E

—

Market cap

$7.82B

Dividend yield

0.0%

Return on equity

157.1%

Sector

Healthcare

Fair value compares CYTK's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.

Related stocks